Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Nkarta, Inc. Common Stock

NKTX

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Last trade $1.23
Day change +$0.02 (+1.65%)
Day range $1.15 – $1.27
Volume 778,183
Market cap $87M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$86.67M
Price / earnings
—
Price / book
0.4×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.29×

Profitability

Earnings per share
-$1.81
Return on assets
-41.97%
Return on equity
-60.01%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
5.79×
Quick ratio
5.79×
Cash ratio
1.72×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$102.31M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NKTX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$6.31M$14.08M$5.89M$5.68M$7.09M$6.41M$12.39M$7.8M
Research and development$29.46M$29.05M$24.99M$25.28M$20.2M$20.78M$24.17M$23.13M
Total operating expenses$35.78M$43.13M$30.88M$30.96M$27.29M$27.19M$36.56M$30.92M
Operating income-$35.78M-$43.13M-$30.88M-$30.96M-$27.29M-$27.19M-$36.56M-$30.92M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$33.33M-$40.37M-$28.37M-$27.41M-$21.72M-$22.98M-$32.01M-$25.94M
Income taxes$0$0$0$0$0$0$0$0
Net income-$33.33M-$40.37M-$28.37M-$27.41M-$21.72M-$22.98M-$32.01M-$25.94M
Net income attributable to common shareholders-$33.33M-$40.37M-$28.37M-$27.41M-$21.72M-$22.98M-$32.01M-$25.94M
EBITDA-$33.72M-$40.4M-$28.54M-$28.7M-$24.98M-$24.86M-$34.27M-$28.64M
Basic earnings per share-$0.45-$0.54-$0.37-$0.37-$0.29-$0.31-$0.43-$0.35
Diluted earnings per share-$0.45-$0.54-$0.37-$0.37-$0.29-$0.31-$0.43-$0.35

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

Nkarta, Inc. announced selection for three scientific presentations at ACR Convergence 2026 in November, including two oral presentations on NKX019's safety profile and clinical activity in idiopathic inflammatory myopathy, and one poster presentation on systemic sclerosis. The company is advancing NKX019, an allogeneic CAR-NK cell therapy targeting CD19 in B-cell-mediated autoimmune diseases, with enrollment ongoing in the Ntrust Phase 1/2 clinical trials across multiple indications.

GlobeNewswire Inc.

Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Nkarta, Inc. (NKTX), a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. President Nadir Mahmood will discuss the company's investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases. The company reported ongoing enrollment in clinical trials at 4 billion cell dose levels and secured FDA agreement for outpatient dosing of NKX019, enabling treatment in community rheumatology centers and expanding patient access.

GlobeNewswire Inc.

Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight

The idiopathic membranous nephropathy (IMN) market is expected to grow from USD 130 million in 2025 to USD 1 billion by 2036, driven by rising disease prevalence, improved diagnostics, and emerging targeted therapies. Multiple pharmaceutical companies are advancing novel treatments including SNP-ACTH (1-39) Gel, zanubrutinib, obinutuzumab, and povetacicept to address the substantial unmet need for more effective and better-tolerated therapies.

GlobeNewswire Inc.

Nkarta to Participate in March Investor Conferences

Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered NK cell therapies for autoimmune diseases, announced its participation in two upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference on March 2, 2026 in Boston, and the Leerink Global Healthcare Conference on March 10, 2026 in Miami. Both presentations will be available via webcast.

GlobeNewswire Inc.

Nkarta to Participate in an April Investor Conference

Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies, announced its participation in the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.